Home › Calculator › IDYA Dividend Calculator 2026
IDYA Dividend DRIP Calculator 2026
5.08% YieldHealthcareIDEAYA Biosciences, Inc. · NASDAQ
Price: $39.37 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When IDYA pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your IDYA snowball 📈
$10,000 in IDYA → $10.77M in 10 years · $44.52/month
About IDEAYA Biosciences, Inc. (IDYA) — Dividend Analysis 2026
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Compare IDYA with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full IDYA DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open IDYA position with:
🌍 IDYA Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold IDYA.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 5.08% | 2.28% | $508 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 4.32% | 1.52% | $432 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 4.06% | 1.26% | $406 / yr |
| 🇬🇧 UK ISA | 0% | 5.08% | 2.28% | $508 / yr |
| 🇬🇧 UK Taxable | 8.75% | 4.64% | 1.84% | $464 / yr |
| 🇨🇦 TFSA | 0% | 5.08% | 2.28% | $508 / yr |
| 🇨🇦 CA Taxable | 25% | 3.81% | 1.01% | $381 / yr |
| 🇦🇺 Super (pension) | 15% | 4.32% | 1.52% | $432 / yr |
| 🇦🇺 AU Taxable | 30% | 3.56% | 0.76% | $356 / yr |
| 🇩🇪 DE Taxable | 26.375% | 3.74% | 0.94% | $374 / yr |
| 🇫🇷 FR Taxable | 30% | 3.56% | 0.76% | $356 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 IDYA Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 IDYA Dividend Payment Schedule
IDYA pays quarterly — 4 times per year. Next ex-div: TBD.
📊 IDYA vs Healthcare Benchmarks
How IDYA compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for IDYA sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ IDYA Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| M-Exempt | 2026-07-07 | 9,550 | $12.86 | $122.8K | ||
| Sale | 2026-07-07 | 9,550 | $40.01 | $382.1K | ||
| M-Exempt | 2026-07-07 | 9,550 | $12.86 | $122.8K | ||
| A-Award | 2026-06-16 | 20,000 | $30.57 | $611.4K | ||
| A-Award | 2026-06-16 | 20,000 | $30.57 | $611.4K | ||
| A-Award | 2026-06-16 | 20,000 | $30.57 | $611.4K | ||
| A-Award | 2026-06-16 | 20,000 | $30.57 | $611.4K | ||
| A-Award | 2026-06-16 | 20,000 | $30.57 | $611.4K | ||
| A-Award | 2026-06-16 | 20,000 | $30.57 | $611.4K | ||
| Other | 2026-03-18 | 297,200 | $31.90 | $9.48M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the IDYA dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
IDEAYA Biosciences, Inc. (IDYA) is currently trading at $39.37, 15% below its 52-week high. The current dividend yield is 5.08% based on an annual payout of $2.00 per share.
IDYA (IDEAYA Biosciences, Inc.) — 5.08% Dividend Yield Analysis
IDEAYA Biosciences, Inc. (IDYA) is a healthcare stock currently trading at $39.37 with a dividend yield of 5.08%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest IDYA News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.